{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,19]],"date-time":"2026-07-19T01:00:10Z","timestamp":1784422810744,"version":"3.55.0"},"reference-count":65,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["109-2314-B-006-054-MY3"],"award-info":[{"award-number":["109-2314-B-006-054-MY3"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020595","name":"National Science and Technology Council","doi-asserted-by":"publisher","award":["NSTC 112-2314-B-006-024"],"award-info":[{"award-number":["NSTC 112-2314-B-006-024"]}],"id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020595","name":"National Science and Technology Council","doi-asserted-by":"publisher","award":["NSTC 113-2314-B-006-072-MY3"],"award-info":[{"award-number":["NSTC 113-2314-B-006-072-MY3"]}],"id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020595","name":"National Science and Technology Council","doi-asserted-by":"publisher","award":["NSTC 113-2321-B-006-014"],"award-info":[{"award-number":["NSTC 113-2321-B-006-014"]}],"id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Schizophrenia Research"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.schres.2025.04.003","type":"journal-article","created":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T03:58:45Z","timestamp":1744343925000},"page":"30-38","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Developing a risk assessment model for treatment-resistant schizophrenia: The role of niacin receptor GPR109A and prostaglandin receptors DP1, EP2, and EP4 in the niacin-induced flushing pathway"],"prefix":"10.1016","volume":"280","author":[{"given":"Chi-Wei","family":"Chiu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bao-Yu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Jia","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huai-Hsuan","family":"Tseng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chih-Chun","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tzu-Yun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fong-Lin","family":"Jang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi-Yu","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Hung","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Po-See","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng-Hsiang","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1\u20132","key":"10.1016\/j.schres.2025.04.003_bb0005","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.brainres.2005.10.068","article-title":"Prostaglandin EP4 receptor agonist protects against acute neurotoxicity","volume":"1066","author":"Ahmad","year":"2005","journal-title":"Brain Res."},{"issue":"3\u20134","key":"10.1016\/j.schres.2025.04.003_bb0010","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.prostaglandins.2009.04.003","article-title":"Emerging roles of PGE2 receptors in models of neurological disease","volume":"91","author":"Andreasson","year":"2010","journal-title":"Prostaglandins Other Lipid Mediat."},{"key":"10.1016\/j.schres.2025.04.003_bb0015","article-title":"Inflammation and JNK's role in niacin-GPR109A diminished flushed effect in microglial and neuronal cells with relevance to schizophrenia","volume":"12","author":"Ansarey","year":"2021","journal-title":"Front. Psychol."},{"issue":"12","key":"10.1016\/j.schres.2025.04.003_bb0020","doi-asserted-by":"crossref","first-page":"898","DOI":"10.2146\/ajhp160219","article-title":"Randomized controlled trial of different aspirin regimens for reduction of niacin-induced flushing","volume":"74","author":"Banka","year":"2017","journal-title":"Am. J. Health Syst. Pharm."},{"issue":"12","key":"10.1016\/j.schres.2025.04.003_bb0025","doi-asserted-by":"crossref","first-page":"3634","DOI":"10.1172\/JCI23626","article-title":"GPR109A (PUMA-G\/HM74A) mediates nicotinic acid\u2013induced flushing","volume":"115","author":"Beny\u00f3","year":"2005","journal-title":"J. Clin. Invest."},{"issue":"9","key":"10.1016\/j.schres.2025.04.003_bb0030","doi-asserted-by":"crossref","first-page":"3583","DOI":"10.1038\/s41380-022-01649-w","article-title":"Relevance of interactions between dopamine and glutamate neurotransmission in schizophrenia","volume":"27","author":"Buck","year":"2022","journal-title":"Mol. Psychiatry"},{"issue":"10","key":"10.1016\/j.schres.2025.04.003_bb0035","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1017\/S0033291716000659","article-title":"Cognition and psychopathology in first-episode psychosis: are they related to inflammation?","volume":"46","author":"Cabrera","year":"2016","journal-title":"Psychol. Med."},{"key":"10.1016\/j.schres.2025.04.003_bb0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.psychres.2022.114762","article-title":"Diminished treatment response in relapsed versus first-episode schizophrenia as revealed by a panel of blood-based biomarkers: a combined cross-sectional and longitudinal study","volume":"316","author":"Cai","year":"2022","journal-title":"Psychiatry Res."},{"issue":"1","key":"10.1016\/j.schres.2025.04.003_bb0045","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1093\/schbul\/sbm153","article-title":"Impaired flush response to niacin skin patch among schizophrenia patients and their nonpsychotic relatives: the effect of genetic loading","volume":"35","author":"Chang","year":"2009","journal-title":"Schizophr. Bull."},{"issue":"9","key":"10.1016\/j.schres.2025.04.003_bb0050","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.3390\/jcm8091443","article-title":"Risk model assessment in early-onset and adult-onset schizophrenia using neurological soft signs","volume":"8","author":"Chen","year":"2019","journal-title":"J. Clin. Med."},{"issue":"1","key":"10.1016\/j.schres.2025.04.003_bb0055","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/s41537-021-00164-1","article-title":"Neurodevelopment regulators miR-137 and miR-34 family as biomarkers for early and adult onset schizophrenia","volume":"7","author":"Chen","year":"2021","journal-title":"NPJ Schizophr."},{"key":"10.1016\/j.schres.2025.04.003_bb0060","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.bbi.2022.07.162","article-title":"Profiling antibody signature of schizophrenia by Escherichia coli proteome microarrays","volume":"106","author":"Chen","year":"2022","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.schres.2025.04.003_bb0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.pnpbp.2023.110926","article-title":"Role of the immune-kynurenine pathway in treatment-resistant schizophrenia","volume":"130","author":"Chen","year":"2024","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.schres.2025.04.003_bb0070","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/bs.acc.2019.08.005","article-title":"Tryptophan in health and disease","volume":"95","author":"Comai","year":"2020","journal-title":"Adv. Clin. Chem."},{"issue":"7","key":"10.1016\/j.schres.2025.04.003_bb0075","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1007\/s40263-022-00932-2","article-title":"A guideline and checklist for initiating and managing clozapine treatment in patients with treatment-resistant schizophrenia","volume":"36","author":"Correll","year":"2022","journal-title":"CNS Drugs"},{"key":"10.1016\/j.schres.2025.04.003_bb0080","series-title":"Novel Antischizophrenia Treatments. Handbook of Experimental Pharmacology","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-642-25758-2_10","article-title":"Glutamatergic synaptic dysregulation in schizophrenia: therapeutic implications","volume":"vol. 213","author":"Coyle","year":"2012"},{"issue":"4","key":"10.1016\/j.schres.2025.04.003_bb0085","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1038\/sj.bjp.0705645","article-title":"EP4 prostanoid receptor-mediated vasodilatation of human middle cerebral arteries","volume":"141","author":"Davis","year":"2004","journal-title":"Br. J. Pharmacol."},{"issue":"3","key":"10.1016\/j.schres.2025.04.003_bb0090","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1017\/S1047951117002426","article-title":"Prolonged prostaglandin-e2-associated periosteal reaction and elevated c-reactive protein levels","volume":"28","author":"Duggan","year":"2017","journal-title":"Cardiol. Young"},{"issue":"3","key":"10.1016\/j.schres.2025.04.003_bb0095","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1038\/nrendo.2010.194","article-title":"Stress responses: the contribution of prostaglandin E2 and its receptors","volume":"7","author":"Furuyashiki","year":"2011","journal-title":"Nat. Rev. Endocrinol."},{"issue":"2","key":"10.1016\/j.schres.2025.04.003_bb1000","doi-asserted-by":"crossref","DOI":"10.1136\/gpsych-2022-100748","article-title":"Attenuated niacin-induced skin flush response in individuals with clinical high risk for psychosis","volume":"35","author":"Gan","year":"2022","journal-title":"Gen. Psychiatry"},{"issue":"11","key":"10.1016\/j.schres.2025.04.003_bb0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2021.103209","article-title":"Systematic discovery of signaling pathways linking immune activation to schizophrenia","volume":"24","author":"Gao","year":"2021","journal-title":"iScience"},{"key":"10.1016\/j.schres.2025.04.003_bb0105","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.eurpsy.2017.09.007","article-title":"Regulation of inflammatory pathways in schizophrenia: a comparative study with bipolar disorder and healthy controls","volume":"47","author":"Garc\u00eda-\u00c1lvarez","year":"2018","journal-title":"Eur. Psychiatr."},{"key":"10.1016\/j.schres.2025.04.003_bb0110","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1146\/annurev.pharmtox.48.113006.094746","article-title":"Nicotinic acid: pharmacological effects and mechanisms of action","volume":"48","author":"Gille","year":"2008","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"issue":"8","key":"10.1016\/j.schres.2025.04.003_bb0115","doi-asserted-by":"crossref","first-page":"2910","DOI":"10.1172\/JCI42273","article-title":"Nicotinic acid\u2013and monomethyl fumarate\u2013induced flushing involves GPR109A expressed by keratinocytes and COX-2\u2013dependent prostanoid formation in mice","volume":"120","author":"Hanson","year":"2010","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.schres.2025.04.003_bb0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.pnpbp.2022.110583","article-title":"Niacin mitigates blood\u2013brain barrier tight junctional proteins dysregulation and cerebral inflammation in ketamine rat model of psychosis: role of GPR109A receptor","volume":"119","author":"Ibrahim","year":"2022","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"issue":"13","key":"10.1016\/j.schres.2025.04.003_bb2000","doi-asserted-by":"crossref","first-page":"7220","DOI":"10.1073\/pnas.96.13.7220","article-title":"Identification of human prostaglandin E synthase: a microsomal, glutathione-dependent, inducible enzyme, constituting a potential novel drug target","volume":"96","author":"Jakobsson","year":"1999","journal-title":"PNAS"},{"issue":"9","key":"10.1016\/j.schres.2025.04.003_bb0125","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1111\/j.1742-1241.2009.02099.x","article-title":"The mechanism and mitigation of niacin-induced flushing","volume":"63","author":"Kamanna","year":"2009","journal-title":"Int. J. Clin. Pract."},{"issue":"6","key":"10.1016\/j.schres.2025.04.003_bb0130","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.3390\/jcm9061848","article-title":"Skinrems\u2014a new method for assessment of the niacin skin flush test response in schizophrenia","volume":"9","author":"Karaku\u0142a-Juchnowicz","year":"2020","journal-title":"J. Clin. Med."},{"issue":"4","key":"10.1016\/j.schres.2025.04.003_bb0135","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.bbalip.2014.07.008","article-title":"Prostaglandin E2-induced inflammation: relevance of prostaglandin E receptors","volume":"1851","author":"Kawahara","year":"2015","journal-title":"Biochim. Biophys. Acta Mol. Cell Biol. Lipids"},{"issue":"2","key":"10.1016\/j.schres.2025.04.003_bb0140","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The positive and negative syndrome scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2025.04.003_bb0145","doi-asserted-by":"crossref","first-page":"2860","DOI":"10.1038\/s41380-019-0401-9","article-title":"Dysregulation of kynurenine metabolism is related to proinflammatory cytokines, attention, and prefrontal cortex volume in schizophrenia","volume":"25","author":"Kindler","year":"2020","journal-title":"Mol. Psychiatry"},{"issue":"15","key":"10.1016\/j.schres.2025.04.003_bb0150","doi-asserted-by":"crossref","first-page":"3951","DOI":"10.1111\/bph.15838","article-title":"Host-directed anti-mycobacterial activity of colchicine, an anti-gout drug, via strengthened host innate resistance reinforced by the IL-1\u03b2\/PGE2 axis","volume":"179","author":"Kwon","year":"2022","journal-title":"Br. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.schres.2025.04.003_bb0155","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1093\/schbul\/sbr054","article-title":"A genome-wide quantitative linkage scan of niacin skin flush response in families with schizophrenia","volume":"39","author":"Lien","year":"2011","journal-title":"Schizophr. Bull."},{"issue":"1","key":"10.1016\/j.schres.2025.04.003_bb0160","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1093\/schbul\/sbl038","article-title":"Familial aggregation in skin flush response to niacin patch among schizophrenic patients and their nonpsychotic relatives","volume":"33","author":"Lin","year":"2007","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2025.04.003_bb0165","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12888-019-2204-6","article-title":"Severity in sustained attention impairment and clozapine-resistant schizophrenia: a retrospective study","volume":"19","author":"Lin","year":"2019","journal-title":"BMC Psychiatr."},{"issue":"1\u20133","key":"10.1016\/j.schres.2025.04.003_bb0170","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.schres.2011.01.018","article-title":"The anti-inflammatory prostaglandin 15d-PGJ2 and its nuclear receptor PPARgamma are decreased in schizophrenia","volume":"128","author":"Mart\u00ednez-Gras","year":"2011","journal-title":"Schizophr. Res."},{"issue":"1","key":"10.1016\/j.schres.2025.04.003_bb0175","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/wps.20693","article-title":"Dopamine and glutamate in schizophrenia: biology, symptoms and treatment","volume":"19","author":"McCutcheon","year":"2020","journal-title":"World Psychiatry"},{"issue":"1\u20133","key":"10.1016\/j.schres.2025.04.003_bb0180","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.schres.2010.03.025","article-title":"Niacin sensitivity and the arachidonic acid pathway in schizophrenia","volume":"122","author":"Messamore","year":"2010","journal-title":"Schizophr. Res."},{"issue":"1","key":"10.1016\/j.schres.2025.04.003_bb0185","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.brainresbull.2008.03.015","article-title":"The high-affinity niacin receptor HM74A is decreased in the anterior cingulate cortex of individuals with schizophrenia","volume":"77","author":"Miller","year":"2008","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.schres.2025.04.003_bb0190","first-page":"892","article-title":"Cytokine alterations in schizophrenia: an updated review","volume":"10","author":"Momtazmanesh","year":"2019","journal-title":"Front. Psychol."},{"issue":"7","key":"10.1016\/j.schres.2025.04.003_bb0195","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/S2215-0366(17)30101-3","article-title":"Brain microglia in psychiatric disorders","volume":"4","author":"Mondelli","year":"2017","journal-title":"Lancet Psychiatry"},{"issue":"1","key":"10.1016\/j.schres.2025.04.003_bb3000","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1080\/15563650500394928","article-title":"Treatment advice on the internet leads to a life-threatening adverse reaction: hypotension associated with niacin overdose","volume":"44","author":"Mularski","year":"2006","journal-title":"Clin. Toxicol."},{"issue":"2","key":"10.1016\/j.schres.2025.04.003_bb0200","doi-asserted-by":"crossref","first-page":"130","DOI":"10.2174\/138161211795049552","article-title":"Kynurenine pathway in schizophrenia: pathophysiological and therapeutic aspects","volume":"17","author":"M\u00fcller","year":"2011","journal-title":"Curr. Pharm. Des."},{"issue":"42","key":"10.1016\/j.schres.2025.04.003_bb4000","doi-asserted-by":"crossref","first-page":"32783","DOI":"10.1074\/jbc.M003505200","article-title":"Regulation of prostaglandin E2 biosynthesis by inducible membrane-associated prostaglandin E2 synthase that acts in concert with cyclooxygenase-2","volume":"275","author":"Murakami","year":"2000","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.schres.2025.04.003_bb0205","first-page":"14","article-title":"Niacin skin flush test: a research tool for studying schizophrenia","volume":"22","author":"Nadalin","year":"2010","journal-title":"Psychiatr. Danub."},{"key":"10.1016\/j.schres.2025.04.003_bb0210","article-title":"Polygenic overlap with body-mass index improves prediction of treatment-resistant schizophrenia","volume":"325","author":"O\u2019Connell","year":"2023","journal-title":"Psychiatry Res."},{"issue":"11786469241239124","key":"10.1016\/j.schres.2025.04.003_bb0215","article-title":"Anthranilic acid, a GPR109A agonist, and schizophrenia","volume":"17","author":"Oxenkrug","year":"2024","journal-title":"Int. J. Tryptophan Res."},{"issue":"5","key":"10.1016\/j.schres.2025.04.003_bb0220","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.7150\/thno.47627","article-title":"Multi-omics study of silicosis reveals the potential therapeutic targets PGD2 and TXA2","volume":"11","author":"Pang","year":"2021","journal-title":"Theranostics"},{"key":"10.1016\/j.schres.2025.04.003_bb0225","doi-asserted-by":"crossref","first-page":"104","DOI":"10.3389\/fmed.2017.00104","article-title":"Prostaglandins and their receptors in eosinophil function and as therapeutic targets","volume":"4","author":"Peinhaupt","year":"2017","journal-title":"Front. Med."},{"key":"10.1016\/j.schres.2025.04.003_bb0230","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2023.109456","article-title":"Potential role of the hydroxyl carboxylic acid receptor type 2 (HCAR2) in microglia pathophysiology: a possible cross-talk with CXC chemokine receptor 1 (CXCR1)","volume":"228","author":"Perrone","year":"2023","journal-title":"Neuropharmacology"},{"issue":"12","key":"10.1016\/j.schres.2025.04.003_bb0235","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1111\/exd.13177","article-title":"Effect of oral eicosapentaenoic acid on epidermal Langerhans cell numbers and PGD2 production in UVR-exposed human skin: a randomised controlled study","volume":"25","author":"Pilkington","year":"2016","journal-title":"Exp. Dermatol."},{"key":"10.1016\/j.schres.2025.04.003_bb0240","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.plefa.2017.05.002","article-title":"Methylnicotinate stimulated prostaglandin synthesis in patients with schizophrenia: a preliminary investigation","volume":"136","author":"Ross","year":"2018","journal-title":"Prostaglandins Leukot. Essent. Fat. Acids"},{"key":"10.1016\/j.schres.2025.04.003_bb0245","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.schres.2023.12.005","article-title":"The kynurenine pathway in treatment-resistant schizophrenia at the crossroads between pathophysiology and pharmacotherapy","volume":"264","author":"Sapienza","year":"2024","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2025.04.003_bb0250","article-title":"Neuroinflammation and kynurenines in schizophrenia: impact on cognition depending on cognitive functioning and modulatory properties in relation to cognitive remediation and aerobic exercise","volume":"38","author":"Sapienza","year":"2024","journal-title":"Schizophr. Res. Cogn."},{"issue":"19","key":"10.1016\/j.schres.2025.04.003_bb0255","doi-asserted-by":"crossref","first-page":"11324","DOI":"10.3390\/ijms231911324","article-title":"Cytokine imbalance as a biomarker of treatment-resistant schizophrenia","volume":"23","author":"Shnayder","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"5","key":"10.1016\/j.schres.2025.04.003_bb0260","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1192\/bjp.bp.115.177261","article-title":"Clozapine v. first- and second-generation antipsychotics in treatment-refractory schizophrenia: systematic review and meta-analysis","volume":"209","author":"Siskind","year":"2016","journal-title":"Br. J. Psychiatry"},{"issue":"10","key":"10.1016\/j.schres.2025.04.003_bb0265","doi-asserted-by":"crossref","DOI":"10.1096\/fj.202200875R","article-title":"Prostanoid receptors in hyperfiltration-mediated glomerular injury: novel agonists and antagonists reveal opposing roles for EP2 and EP4 receptors","volume":"36","author":"Srivastava","year":"2022","journal-title":"FASEB J."},{"issue":"4","key":"10.1016\/j.schres.2025.04.003_bb0270","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1093\/schbul\/sbx150","article-title":"Identification of the niacin-blunted subgroup of schizophrenia patients from mood disorders and healthy individuals in Chinese population","volume":"44","author":"Sun","year":"2018","journal-title":"Schizophr. Bull."},{"issue":"1\u20133","key":"10.1016\/j.schres.2025.04.003_bb0275","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.schres.2009.03.005","article-title":"Schizophrenia, \u201cjust the facts\u201d 4. Clinical features and conceptualization","volume":"110","author":"Tandon","year":"2009","journal-title":"Schizophr. Res."},{"issue":"6","key":"10.1016\/j.schres.2025.04.003_bb5000","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1097\/PPO.0000000000000003","article-title":"An inflammatory mediator, prostaglandin E2, in colorectal cancer","volume":"19","author":"Wang","year":"2013","journal-title":"Cancer J."},{"issue":"3","key":"10.1016\/j.schres.2025.04.003_bb0280","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/S0920-9964(97)00100-X","article-title":"Niacin skin flush in schizophrenia: a preliminary report","volume":"29","author":"Ward","year":"1998","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2025.04.003_bb0285","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2021.103239","article-title":"Dysregulation of phospholipase and cyclooxygenase expression is involved in schizophrenia","volume":"64","author":"Yang","year":"2021","journal-title":"EBioMedicine"},{"issue":"2","key":"10.1016\/j.schres.2025.04.003_bb0290","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1093\/schbul\/sbv130","article-title":"Prevalence and specificity of the abnormal niacin response: a potential endophenotype marker in schizophrenia","volume":"42","author":"Yao","year":"2015","journal-title":"Schizophr. Bull."},{"issue":"1","key":"10.1016\/j.schres.2025.04.003_bb0295","doi-asserted-by":"crossref","DOI":"10.1038\/s41537-022-00252-w","article-title":"Niacin skin flush and membrane polyunsaturated fatty acids in schizophrenia from the acute state to partial remission: a dynamic relationship","volume":"8","author":"Yu","year":"2022","journal-title":"Schizophrenia"},{"key":"10.1016\/j.schres.2025.04.003_bb0300","doi-asserted-by":"crossref","DOI":"10.1016\/j.pnpbp.2023.110740","article-title":"Peripheral cytokine levels across psychiatric disorders: a systematic review and network meta-analysis","volume":"125","author":"Zhang","year":"2023","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"}],"container-title":["Schizophrenia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996425001239?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996425001239?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T14:30:21Z","timestamp":1774881021000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920996425001239"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":65,"alternative-id":["S0920996425001239"],"URL":"https:\/\/doi.org\/10.1016\/j.schres.2025.04.003","relation":{},"ISSN":["0920-9964"],"issn-type":[{"value":"0920-9964","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Developing a risk assessment model for treatment-resistant schizophrenia: The role of niacin receptor GPR109A and prostaglandin receptors DP1, EP2, and EP4 in the niacin-induced flushing pathway","name":"articletitle","label":"Article Title"},{"value":"Schizophrenia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.schres.2025.04.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}